Med Sci (Paris)
Volume 29, Number 6-7, Juin–Juillet 2013
Le réseau international des Instituts Pasteur
Page(s) 647 - 655
Section M/S Revues
Published online 12 July 2013
  1. Anstey NM, Russell B, Yeo TW, Price RN. The pathophysiology of vivax malaria. Trends Parasitol 2009 ; 25 : 220–227. [CrossRef] [PubMed] [Google Scholar]
  2. Stratton L, O’Neill MS, Kruk ME, Bell ML. The persistent problem of malaria: addressing the fundamental causes of a global killer. Soc Sci Med 2008 ; 67 : 854–862. [CrossRef] [PubMed] [Google Scholar]
  3. Trape JF. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg 2001 ; 64 : 12–17. [PubMed] [Google Scholar]
  4. O’Meara WP, Mangeni JN, Steketee R, Greenwood B. Changes in the burden of malaria in sub-Saharan Africa. Lancet Infect Dis 2012 ; 10 : 545–555. [CrossRef] [Google Scholar]
  5. World Health Organization. World malaria report 2011. Geneva : WHO, 2011. [Google Scholar]
  6. Murray CJ, Rosenfeld LC, Lim SS, et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012 ; 379 : 413–431. [CrossRef] [PubMed] [Google Scholar]
  7. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002 ; 2 : 209–218. [CrossRef] [PubMed] [Google Scholar]
  8. World Health Organization. Guidelines for the treatment of malaria, 2nd ed. WHO : 2011. [Google Scholar]
  9. Amaratunga C, Sreng S, Suon S, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis 2012 ; 12 : 851–858. [CrossRef] [PubMed] [Google Scholar]
  10. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009 ; 361 : 455–467. [Google Scholar]
  11. Noedl H, Se Y, Schaecher K, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008 ; 359 : 2619–2620. [Google Scholar]
  12. Phyo AP, Nkhoma S, Stepniewska K, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012 ; 379 : 1960–1966. [CrossRef] [PubMed] [Google Scholar]
  13. Enserink M. If artemisinin drugs fail, what’s plan B? Science 2010 ; 328 : 846. [CrossRef] [PubMed] [Google Scholar]
  14. Legrand E, Volney B, Meynard JB, et al. In vitro monitoring of Plasmodium falciparum drug resistance in French Guiana: a synopsis of continuous assessment from 1994 to 2005. Antimicrob Agents Chemother 2008 ; 52 : 288–298. [CrossRef] [PubMed] [Google Scholar]
  15. Lim P, Wongsrichanalai C, Chim P, et al. Decreased in vitro susceptibility of Plasmodium falciparum isolates to artesunate, mefloquine, chloroquine, and quinine in Cambodia from 2001 to 2007. Antimicrob Agents Chemother 2010 ; 54 : 2135–2142. [CrossRef] [PubMed] [Google Scholar]
  16. Andriantsoanirina V, Ratsimbasoa A, Bouchier C, et al. Plasmodium falciparum drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility. Antimicrob Agents Chemother 2009 ; 53 : 4588–4597. [CrossRef] [PubMed] [Google Scholar]
  17. Ekala MT, Khim N, Legrand E, Sequence analysis of Plasmodium falciparum cytochrome b in multiple geographic sites. Malar J 2007 ; 6 : 164. [CrossRef] [PubMed] [Google Scholar]
  18. Jambou R, Legrand E, Niang M, et al. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 2005 ; 366 : 1960–1963. [CrossRef] [PubMed] [Google Scholar]
  19. Legrand E, Volney B, Meynard JB, et al. Resistance to dihydroartemisinin. Emerg Infect Dis 2007 ; 13 : 808–809. [CrossRef] [PubMed] [Google Scholar]
  20. Ibrahim ML, Khim N, Adam HH, et al. Polymorphism of PfATPase in Niger: detection of three new point mutations. Malar J 2009 ; 8 : 28. [CrossRef] [PubMed] [Google Scholar]
  21. Jambou R, Martinelli A, Pinto J, et al. Geographic structuring of the Plasmodium falciparum sarco(endo)plasmic reticulum Ca2+ ATPase (PfSERCA) gene diversity. PLoS One 2010 ; 5 : e9424. [CrossRef] [PubMed] [Google Scholar]
  22. Andriantsoanirina V, Ratsimbasoa A, Bouchier C, et al. Chloroquine clinical failures in P. falciparum malaria are associated with mutant Pfmdr-1, not Pfcrt in Madagascar. PLoS One 2010 ; 5 : e13281. [CrossRef] [PubMed] [Google Scholar]
  23. Legrand E, Yrinesi J, Ekala MT, et al. Discordant temporal evolution of Pfcrt and Pfmdr1 genotypes and Plasmodium falciparum in vitro drug susceptibility to 4-aminoquinolines after drug policy change in French Guiana. Antimicrob Agents Chemother 2012 ; 56 : 1382–1389. [CrossRef] [PubMed] [Google Scholar]
  24. Ariey F, Fandeur T, Durand R, et al. Invasion of Africa by a single pfcrt allele of South-East Asian type. Malar J 2006 ; 5 : 34. [CrossRef] [PubMed] [Google Scholar]
  25. Andriantsoanirina V, Bouchier C, Tichit M, et al. Origins of the recent emergence of Plasmodium falciparum pyrimethamine resistance alleles in Madagascar. Antimicrob Agents Chemother 2010 ; 54 : 2323–2329. [CrossRef] [PubMed] [Google Scholar]
  26. Menard D, Randrianarivo-Solofoniaina AE, Ahmed BS, et al. Drug-resistant malaria parasites introduced into Madagascar from Comoros Islands. Emerg Infect Dis 2007 ; 13 : 1759–1762. [CrossRef] [PubMed] [Google Scholar]
  27. Ariey F, Duchemin JB, Robert V. Metapopulation concepts applied to falciparum malaria and their impacts on the emergence and spread of chloroquine resistance. Infect Genet Evol 2003 ; 2 : 185–192. [CrossRef] [PubMed] [Google Scholar]
  28. Ariey F, Robert V. The puzzling links between malaria transmission and drug resistance. Trends Parasitol 2003 ; 19 : 158–161. [CrossRef] [PubMed] [Google Scholar]
  29. Noranate N, Durand R, Tall A, et al. Rapid dissemination of Plasmodium falciparum drug resistance despite strictly controlled antimalarial use. PLoS One 2007 ; 2 : e139. [CrossRef] [PubMed] [Google Scholar]
  30. Steenkeste N, Dillies MA, Khim N, et al. FlexiChip package: an universal microarray with a dedicated analysis software for high-thoughput SNPs detection linked to anti-malarial drug resistance. Malar J 2009 ; 8 : 229. [CrossRef] [PubMed] [Google Scholar]
  31. Ibrahim ML, Steenkeste N, Khim N, et al. Field-based evidence of fast, global increase of Plasmodium falciparum drug-resistance by DNA-microarrays, PCR/RFLP in Niger. Malar J 2009 ; 8 : 32. [CrossRef] [PubMed] [Google Scholar]
  32. Andriantsoanirina V, Lascombes V, Ratsimbasoa A, et al. Rapid detection of point mutations in Plasmodium falciparum genes associated with antimalarial drugs resistance by using high-resolution melting analysis. J Microbiol Methods 2009 ; 78 : 165–170. [CrossRef] [PubMed] [Google Scholar]
  33. Rason MA, Randriantsoa T, Andrianantenaina H, et al. Performance and reliability of the SYBR Green I based assay for the routine monitoring of susceptibility of Plasmodium falciparum clinical isolates. Trans R Soc Trop Med Hyg 2008 ; 102 : 346–351. [CrossRef] [PubMed] [Google Scholar]
  34. World Health Organization. Global plan for artemisinin resistance containment (GPARC). Geneva : WHO, 2011. [Google Scholar]
  35. Witkowski B, Khim N, Chim P, et al. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Chemother 2013 ; 57 : 914–923. [Google Scholar]
  36. World Health Organization. Methods for surveillance of antimalarial drug efficacy. Geneva : WHO Press, 2009. [Google Scholar]
  37. Basco LK., Field application of in vitro assays sensitivity of human malaria parasites antimalarial drugs. Geneva : WHO Press, 2007 [Google Scholar]
  38. Sidhu AB, Verdier-Pinard V, Fidock DA. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 2002 ; 298 : 210–213. [CrossRef] [PubMed] [Google Scholar]
  39. Warhurst DC. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 2001 ; 344 : 299–302. [CrossRef] [PubMed] [Google Scholar]
  40. Sanchez CP, Stein WD, Lanzer M. Is PfCRT a channel or a carrier? Two competing models explaining chloroquine resistance in Plasmodium falciparum . Trends Parasitol 2007 ; 23 : 332–339. [CrossRef] [PubMed] [Google Scholar]
  41. Cooper RA, Lane KD, Deng B, et al. Mutations in transmembrane domains 1, 4 and 9 of the Plasmodium falciparum chloroquine resistance transporter alter susceptibility to chloroquine, quinine and quinidine. Mol Microbiol 2007 ; 63 : 270–282. [CrossRef] [PubMed] [Google Scholar]
  42. Tinto H, Guekoun L, Zongo I, et al. Chloroquine-resistance molecular markers (Pfcrt T76 and Pfmdr-1 Y86) and amodiaquine resistance in Burkina Faso. Trop Med Int Health 2008 ; 13 : 238–240. [Google Scholar]
  43. Laufer MK, Thesing PC, Eddington ND, et al. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 2006 ; 355 : 1959–1966. [Google Scholar]
  44. Noranate N, Durand R, Tall A, et al. Rapid dissemination of Plasmodium falciparum drug resistance despite strictly controlled antimalarial use. PLoS One 2007 ; 2 : e139. [CrossRef] [PubMed] [Google Scholar]
  45. Duraisingh MT, Cowman AF. Contribution of the pfmdr1 gene to antimalarial drug-resistance. Acta Trop 2005 ; 94 : 181–190. [CrossRef] [PubMed] [Google Scholar]
  46. Nishiyama Y, Okuda Y, Kim HS, et al. Genetic analysis of mefloquine-resistant mechanism of Plasmodium falciparum. Nucleic Acids Symp Ser (Oxf) 2004 ; 48 : 163–164. [CrossRef] [PubMed] [Google Scholar]
  47. Price RN, Uhlemann AC, Brockman A, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004 ; 364 : 438–447. [CrossRef] [PubMed] [Google Scholar]
  48. Pickard AL, Wongsrichanalai C, Purfield A, et al. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob Agents Chemother 2003 ; 47 : 2418–2423. [CrossRef] [PubMed] [Google Scholar]
  49. Cowman AF, Galatis D, Thompson JK. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc Natl Acad Sci USA 1994 ; 91 : 1143–1147. [CrossRef] [Google Scholar]
  50. Foote SJ, Cowman AF. The mode of action and the mechanism of resistance to antimalarial drugs. Acta Trop 1994 ; 56 : 157–171. [CrossRef] [PubMed] [Google Scholar]
  51. Sibley CH, Hyde JE, Sims PF, et al. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum : what next?. Trends Parasitol 2001 ; 17 : 582–588. [CrossRef] [PubMed] [Google Scholar]
  52. Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev 2005 ; 57 : 117–145. [Google Scholar]
  53. Srivastava IK, Morrisey JM, Darrouzet E, et al. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol Microbiol 1999 ; 33 : 704–711. [CrossRef] [PubMed] [Google Scholar]
  54. Nkrumah LJ, Riegelhaupt PM, Moura P, et al. Probing the multifactorial basis of Plasmodium falciparum quinine resistance: evidence for a strain-specific contribution of the sodium-proton exchanger PfNHE. Mol Biochem Parasitol 2009 ; 165 : 122–131. [CrossRef] [PubMed] [Google Scholar]
  55. Ferdig, MT, Cooper RA, Mu J, et al. Dissecting the loci of low-level quinine resistance in malaria parasites. Mol Microbiol 2004 ; 52 : 985–997. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.